Conference
A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.
Authors
Bjarnason GA; Basappa NS; Knox JJ; Kollmannsberger CK; Reaume MNN; Lalewski P; Macfarlane RJ; MacKenzie MJ; Hotte SJ; Heng DVC
Volume
31
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
May 20, 2013
Name of conference
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
IL, Chicago
Conference start date
May 31, 2013
Conference end date
June 4, 2013
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X